Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its blockbuster semaglutide (GLP-1 RA)-based therapies, Wegovy for obesity and Ozempic for type II diabetes (T2D). While maintaining its leadership in metabolic diseases, the company is also making significant efforts to diversify its...